Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Forward Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$7,285,127

2,212 payments

Through program year 2025, Forward Clinical Trials is reported as receiving $7,285,127 in research payments, across 2,212 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $12,034 1
2024 Research $1,081,100 39
2023 Research $1,295,463 1,822
2022 Research $878,220 65
2021 Research $1,929,414 167
2020 Research $1,669,493 62
2019 Research $419,403 56

Breakdown

Who paid Research payments · program years 2019–2025
  1. Incyte Corporation $2,419,414 262 payments
  2. Ucb SA $2,332,978 113 payments
  3. Moderna TX, Inc. $1,719,741 1,769 payments
  4. Pfizer Inc. $347,333 33 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $174,374 7 payments
  6. Novartis Pharmaceuticals Corporation $127,051 7 payments
  7. Biohaven Pharmaceutical Holding Company Ltd. $87,033 8 payments
  8. E.R. Squibb & Sons, L.L.C. $44,036 5 payments
  9. Galderma Research & Development, LLC $16,178 4 payments
  10. AstraZeneca Pharmaceuticals LP $12,034 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age $980,020 20 payments
  2. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa $913,877 32 payments
  3. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $651,285 1,653 payments
  4. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa $461,371 26 payments
  5. Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo $429,356 20 payments
  6. A Phase 3, Randomized, Double-Blind, Placebocontrolled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa $410,822 2 payments
  7. A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa $356,987 30 payments
  8. A 26Week Phase 2B 2Part Randomized Doubleblind Placebo Controlled Parallel Group Doseranging Study to Evaluate the Efficacy and Safety of Pf06882961 Administration in Adults With Obesity $341,836 31 payments
  9. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo $320,542 19 payments
  10. TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis $265,125 19 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record